论文部分内容阅读
Lorcaserin的减肥作用比脂肪酶抑制剂奥司利他稍弱或者接近,但比西布曲明弱。因此决定lorcaserin能否上市的主要因素是其安全性。
Lorcaserin is slightly weaker or closer to weight loss than the lipase inhibitor oseltamivir, but weaker than sibutramine. Therefore, the main factor that determines whether lorcaserin can be listed is its safety.